LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 8 of total 8

Search options

  1. Article ; Online: Reprogramming of pyrimidine nucleotide metabolism supports vigorous cell proliferation of normal and malignant T cells.

    Watanabe, Tatsuro / Yamamoto, Yuta / Kurahashi, Yuki / Kawasoe, Kazunori / Kidoguchi, Keisuke / Ureshino, Hiroshi / Kamachi, Kazuharu / Yoshida-Sakai, Nao / Fukuda-Kurahashi, Yuki / Nakamura, Hideaki / Okada, Seiji / Sueoka, Eisaburo / Kimura, Shinya

    Blood advances

    2024  Volume 8, Issue 6, Page(s) 1345–1358

    Abstract: Abstract: Adult T-cell leukemia/lymphoma (ATL) is triggered by infection with human T-cell lymphotropic virus-1 (HTLV-1). Here, we describe the reprogramming of pyrimidine biosynthesis in both normal T cells and ATL cells through regulation of uridine- ... ...

    Abstract Abstract: Adult T-cell leukemia/lymphoma (ATL) is triggered by infection with human T-cell lymphotropic virus-1 (HTLV-1). Here, we describe the reprogramming of pyrimidine biosynthesis in both normal T cells and ATL cells through regulation of uridine-cytidine kinase 2 (UCK2), which supports vigorous proliferation. UCK2 catalyzes the monophosphorylation of cytidine/uridine and their analogues during pyrimidine biosynthesis and drug metabolism. We found that UCK2 was overexpressed aberrantly in HTLV-1-infected T cells but not in normal T cells. T-cell activation via T-cell receptor (TCR) signaling induced expression of UCK2 in normal T cells. Somatic alterations and epigenetic modifications in ATL cells activate TCR signaling. Therefore, we believe that expression of UCK2 in HTLV-1-infected cells is induced by dysregulated TCR signaling. Recently, we established azacitidine-resistant (AZA-R) cells showing absent expression of UCK2. AZA-R cells proliferated normally in vitro, whereas UCK2 knockdown inhibited ATL cell growth. Although uridine and cytidine accumulated in AZA-R cells, possibly because of dysfunction of pyrimidine salvage biosynthesis induced by loss of UCK2 expression, the amount of UTP and CTP was almost the same as in parental cells. Furthermore, AZA-R cells were more susceptible to an inhibitor of dihydroorotic acid dehydrogenase, which performs the rate-limiting enzyme of de novo pyrimidine nucleotide biosynthesis, and more resistant to dipyridamole, an inhibitor of pyrimidine salvage biosynthesis, suggesting that AZA-R cells adapt to UCK2 loss by increasing de novo pyrimidine nucleotide biosynthesis. Taken together, the data suggest that fine-tuning pyrimidine biosynthesis supports vigorous cell proliferation of both normal T cells and ATL cells.
    MeSH term(s) Adult ; Humans ; Pyrimidines ; Uridine/metabolism ; Cell Proliferation ; Cytidine ; Human T-lymphotropic virus 1 ; Pyrimidine Nucleotides ; Receptors, Antigen, T-Cell ; T-Lymphocytes/metabolism
    Chemical Substances Pyrimidines ; Uridine (WHI7HQ7H85) ; Cytidine (5CSZ8459RP) ; Pyrimidine Nucleotides ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2024-01-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023011131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.

    Kamachi, Kazuharu / Ureshino, Hiroshi / Watanabe, Tatsuro / Yoshida-Sakai, Nao / Fukuda-Kurahashi, Yuki / Kawasoe, Kazunori / Hoshiko, Toshimi / Yamamoto, Yuta / Kurahashi, Yuki / Kimura, Shinya

    Cancer research communications

    2023  Volume 3, Issue 2, Page(s) 297–308

    Abstract: The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2-selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. This regimen results in low toxicity, high ... ...

    Abstract The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2-selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. This regimen results in low toxicity, high response rates, and potentially durable remission; however, because of low oral bioavailability, these conventional HMAs must be administered intravenously or subcutaneously. A combination of oral HMAs and Ven would provide a therapeutic advantage over parenteral administration of drugs and improve quality of life by reducing the number of hospital visits. Previously, we showed the promising oral bioavailability and antileukemia effects of a new HMA, OR2100 (OR21). Here, we investigated the efficacy and underlying mechanism of OR21 when used in combination with Ven to treat AML. OR21/Ven showed synergistic antileukemia effects
    Significance: The standard treatment for elderly patients with AML is Ven combined with HMAs. OR21, a new oral HMA plus Ven showed synergistic antileukemia effects
    MeSH term(s) Humans ; Animals ; Mice ; Aged ; Quality of Life ; Azacitidine/pharmacology ; Antineoplastic Agents/pharmacology ; Leukemia, Myeloid, Acute/drug therapy
    Chemical Substances venetoclax (N54AIC43PW) ; Azacitidine (M801H13NRU) ; Antineoplastic Agents
    Language English
    Publishing date 2023-02-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2767-9764
    ISSN (online) 2767-9764
    DOI 10.1158/2767-9764.CRC-22-0259
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation.

    Kawasoe, Kazunori / Watanabe, Tatsuro / Yoshida-Sakai, Nao / Yamamoto, Yuta / Kurahashi, Yuki / Kidoguchi, Keisuke / Ureshino, Hiroshi / Kamachi, Kazuharu / Fukuda-Kurahashi, Yuki / Kimura, Shinya

    Cancers

    2023  Volume 15, Issue 20

    Abstract: The recent evolution of molecular targeted therapy has improved clinical outcomes in several human malignancies. The translocation of anaplastic lymphoma kinase (ALK) was originally identified in anaplastic large-cell lymphoma (ALCL) and subsequently in ... ...

    Abstract The recent evolution of molecular targeted therapy has improved clinical outcomes in several human malignancies. The translocation of anaplastic lymphoma kinase (ALK) was originally identified in anaplastic large-cell lymphoma (ALCL) and subsequently in non-small cell lung carcinoma (NSCLC). Since
    Language English
    Publishing date 2023-10-21
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15205089
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.

    Yoshida-Sakai, Nao / Watanabe, Tatsuro / Yamamoto, Yuta / Ureshino, Hiroshi / Kamachi, Kazuharu / Kurahashi, Yuki / Fukuda-Kurahashi, Yuki / Kimura, Shinya

    International journal of cancer

    2021  Volume 150, Issue 7, Page(s) 1184–1197

    Abstract: Adult T-cell leukemia-lymphoma (ATL) is an aggressive neoplasm derived from T-cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Recently, we reported that regional DNA hypermethylation in HTLV-1-infected T-cells reflects the disease status ...

    Abstract Adult T-cell leukemia-lymphoma (ATL) is an aggressive neoplasm derived from T-cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Recently, we reported that regional DNA hypermethylation in HTLV-1-infected T-cells reflects the disease status of ATL and the anti-ATL effects of DNA demethylating agents, including azacitidine (AZA), decitabine (DAC) and a new DAC prodrug, OR-2100 (OR21), which we developed. Here, to better understand the mechanisms underlying drug resistance, we generated AZA-, DAC- and OR21-resistant (AZA-R, DAC-R and OR21-R, respectively) cells from the ATL cell line TL-Om1 and the HTLV-1-infected cell line MT-2 via long-term drug exposure. The efficacy of OR21 was almost the same as that of DAC, indicating that the pharmacodynamics of OR21 were due to release of DAC from OR21. Resistant cells did not show cellular responses observed in parental cells induced by treatment with drugs, including growth suppression, depletion of DNA methyltransferase DNMT1 and DNA hypomethylation. We also found that reduced expression of deoxycytidine kinase (DCK) correlated with lower susceptibility to DAC/OR21 and that reduced expression of uridine cytidine kinase2 (UCK2) correlated with reduced susceptibility to AZA. DCK and UCK2 catalyze phosphorylation of DAC and AZA, respectively; reconstitution of expression reversed the resistant phenotypes. A large homozygous deletion in DCK and a homozygous splice donor site mutation in UCK2 were identified in DAC-R TL-Om1 and AZA-R TL-Om1, respectively. Both genomic mutations might lead to loss of protein expression. Thus, inactivation of UCK2 and DCK might be a putative cause of phenotypes that are resistant to AZA and DAC/OR21, respectively.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Azacitidine/therapeutic use ; Cell Line, Tumor ; DNA Methylation/drug effects ; Decitabine/therapeutic use ; Deoxycytidine Kinase/physiology ; Drug Resistance, Neoplasm ; Humans ; Leukemia-Lymphoma, Adult T-Cell/drug therapy ; Leukemia-Lymphoma, Adult T-Cell/metabolism ; Pyridines/therapeutic use ; Pyrimidines/metabolism ; Uridine Kinase/physiology
    Chemical Substances Antineoplastic Agents ; OR-2100 ; Pyridines ; Pyrimidines ; Decitabine (776B62CQ27) ; UCK2 protein, human (EC 2.7.1.48) ; Uridine Kinase (EC 2.7.1.48) ; Deoxycytidine Kinase (EC 2.7.1.74) ; pyrimidine (K8CXK5Q32L) ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2021-12-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218257-9
    ISSN 1097-0215 ; 0020-7136
    ISSN (online) 1097-0215
    ISSN 0020-7136
    DOI 10.1002/ijc.33901
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.

    Kurahashi, Yuki / Watanabe, Tatsuro / Yamamoto, Yuta / Ureshino, Hiroshi / Kamachi, Kazuharu / Yoshida-Sakai, Nao / Fukuda-Kurahashi, Yuki / Yamashita, Satoshi / Hattori, Naoko / Nakamura, Hideaki / Kawaguchi, Atsushi / Ushijima, Toshikazu / Sueoka, Eisaburo / Kimura, Shinya

    Blood advances

    2022  Volume 7, Issue 8, Page(s) 1545–1559

    Abstract: Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature CD4+ T cells caused by human T-cell lymphotropic virus type 1 (HTLV-1)-induced T-cell transformation. After infection with HTLV-1, it takes several decades for HTLV-1 carriers to develop ATL. ...

    Abstract Adult T-cell leukemia/lymphoma (ATL) is a malignancy of mature CD4+ T cells caused by human T-cell lymphotropic virus type 1 (HTLV-1)-induced T-cell transformation. After infection with HTLV-1, it takes several decades for HTLV-1 carriers to develop ATL. The prognosis of ATL remains poor despite several new agents being approved in the last few years. Recently, it has been noted that epigenetic abnormalities, both DNA methylation and trimethylation at histone H3Lys27 (H3K27me3), contribute to ATL leukemogenesis. Here, we investigated the effect of combination treatment with DNA demethylating agents (azacitidine [AZA], decitabine (DAC), and OR-2100 (OR21), which is a silylated derivative of DAC) and inhibitors of enhancer of zeste homolog 2 (EZH2) (EPZ-6438 and DS-3201b), which catalyze trimethylation of H3K27, in ATL. The combination of DAC and OR21 but not AZA with EZH inhibitors exhibited synergistic anti-ATL effects in vitro and in vivo, concomitant with DNA demethylation and reduction of H3K27me3. The combination induced gene expression reprogramming. Dual-specificity phosphatase 5 (DUSP5), an extracellular signal-regulated kinase (ERK)-specific phosphatase, was identified as a key molecule that mediated the inhibitory effect of combination treatment by inactivating the ERK signaling pathway. DUSP5 was downregulated by DNA methylation and H3K27me3 accumulation in the promoter region in HTLV-1-infected cells from patients with ATL during ATL leukemogenesis. The present results demonstrate that dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth by restoring DUSP5, and that dual targeting of aberrant DNA and histone methylation is a feasible therapeutic approach for ATL.
    MeSH term(s) Adult ; Humans ; Histones/metabolism ; Leukemia-Lymphoma, Adult T-Cell/drug therapy ; Leukemia-Lymphoma, Adult T-Cell/genetics ; Human T-lymphotropic virus 1/genetics ; Neoplasms/genetics ; DNA Methylation ; Azacitidine/pharmacology ; DNA/metabolism
    Chemical Substances Histones ; Azacitidine (M801H13NRU) ; DNA (9007-49-2)
    Language English
    Publishing date 2022-12-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2022008362
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.

    Kamachi, Kazuharu / Ureshino, Hiroshi / Watanabe, Tatsuro / Yoshida, Nao / Yamamoto, Yuta / Kurahashi, Yuki / Fukuda-Kurahashi, Yuki / Hayashi, Yoshihiro / Hirai, Hideyo / Yamashita, Satoshi / Ushijima, Toshikazu / Okada, Seiji / Kimura, Shinya

    Cancer letters

    2021  Volume 526, Page(s) 273–283

    Abstract: ABL1 tyrosine kinase inhibitors (TKIs) dramatically improve the prognosis of chronic myeloid leukemia (CML), but 10-20% of patients achieve suboptimal responses with low TKIs sensitivity. Furthermore, residual leukemic stem cells (LSCs) are involved in ... ...

    Abstract ABL1 tyrosine kinase inhibitors (TKIs) dramatically improve the prognosis of chronic myeloid leukemia (CML), but 10-20% of patients achieve suboptimal responses with low TKIs sensitivity. Furthermore, residual leukemic stem cells (LSCs) are involved in the molecular relapse after TKIs discontinuation. Aberrant DNA hypermethylation contributes to low TKIs sensitivity and the persistence of LSCs in CML. DNMT1 is a key regulator of hematopoietic stem cells, suggesting that aberrant DNA hypermethylation targeting DNMT1 represents a potential therapeutic target for CML. We investigated the efficacy of OR-2100 (OR21), the first orally available single-compound prodrug of decitabine. OR21 exhibited anti-tumor effects as a monotherapy, and in combination therapy it increased TKI-induced apoptosis and induction of tumor suppressor genes including PTPN6 encoding SHP-1 in CML cells. OR21 in combination with imatinib significantly suppressed tumor growth in a xenotransplant model. OR21 and combination therapy decreased the abundance of LSCs and inhibited engraftment in a BCR-ABL1-transduced mouse model. These results demonstrate that targeting DNMT1 using OR21 exerts anti-tumor effects and impairs LSCs in CML. Therefore, combination treatment of TKIs and OR21 represents a promising treatment strategy in CML.
    MeSH term(s) Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; DNA (Cytosine-5-)-Methyltransferase 1/antagonists & inhibitors ; DNA (Cytosine-5-)-Methyltransferase 1/metabolism ; Disease Models, Animal ; Drug Synergism ; Humans ; Jurkat Cells ; K562 Cells ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology ; Mice ; Molecular Targeted Therapy ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacology ; Pyridines/administration & dosage ; Pyridines/pharmacology ; Random Allocation ; Xenograft Model Antitumor Assays
    Chemical Substances OR-2100 ; Protein Kinase Inhibitors ; Pyridines ; DNA (Cytosine-5-)-Methyltransferase 1 (EC 2.1.1.37) ; DNMT1 protein, human (EC 2.1.1.37)
    Language English
    Publishing date 2021-12-04
    Publishing country Ireland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 195674-7
    ISSN 1872-7980 ; 0304-3835
    ISSN (online) 1872-7980
    ISSN 0304-3835
    DOI 10.1016/j.canlet.2021.11.032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.

    Ureshino, Hiroshi / Kurahashi, Yuki / Watanabe, Tatsuro / Yamashita, Satoshi / Kamachi, Kazuharu / Yamamoto, Yuta / Fukuda-Kurahashi, Yuki / Yoshida-Sakai, Nao / Hattori, Naoko / Hayashi, Yoshihiro / Kawaguchi, Atsushi / Tohyama, Kaoru / Okada, Seiji / Harada, Hironori / Ushijima, Toshikazu / Kimura, Shinya

    Molecular cancer therapeutics

    2021  Volume 20, Issue 8, Page(s) 1412–1421

    Abstract: DNA methyltransferase inhibitors have improved the prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, because these agents are easily degraded by cytidine deaminase (CDA), they must be administered intravenously or ... ...

    Abstract DNA methyltransferase inhibitors have improved the prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, because these agents are easily degraded by cytidine deaminase (CDA), they must be administered intravenously or subcutaneously. Recently, two orally bioavailable DNA methyltransferase inhibitors, CC-486 and ASTX727, were approved. In previous work, we developed 5-O-trialkylsilylated decitabines that resist degradation by CDA. However, the effects of silylation of a deoxynucleotide analog and enzymatic cleavage of silylation have not been fully elucidated. Enteric administration of OR21 in a cynomolgus monkey model led to high plasma concentrations and hypomethylation, and in a mouse model, oral administration of enteric-coated OR21 led to high plasma concentrations. The drug became biologically active after release of decitabine (DAC) from OR21 following removal of the 5'-O-trisilylate substituent. Toxicities were tolerable and lower than those of DAC. Transcriptome and methylome analysis of MDS and AML cell lines revealed that OR21 increased expression of genes associated with tumor suppression, cell differentiation, and immune system processes by altering regional promoter methylation, indicating that these pathways play pivotal roles in the action of hypomethylating agents. OR21 induced cell differentiation via upregulation of the late cell differentiation drivers
    MeSH term(s) Administration, Oral ; Animals ; Antimetabolites, Antineoplastic/pharmacology ; Apoptosis ; Cell Proliferation ; Decitabine/chemistry ; Decitabine/pharmacology ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/metabolism ; Leukemia, Myeloid, Acute/pathology ; Macaca fascicularis ; Mice ; Mice, Inbred BALB C ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/metabolism ; Myelodysplastic Syndromes/pathology ; Silanes/chemistry ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
    Chemical Substances Antimetabolites, Antineoplastic ; Silanes ; Decitabine (776B62CQ27)
    Language English
    Publishing date 2021-05-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2063563-1
    ISSN 1538-8514 ; 1535-7163
    ISSN (online) 1538-8514
    ISSN 1535-7163
    DOI 10.1158/1535-7163.MCT-20-1125
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.

    Watanabe, Tatsuro / Yamashita, Satoshi / Ureshino, Hiroshi / Kamachi, Kazuharu / Kurahashi, Yuki / Fukuda-Kurahashi, Yuki / Yoshida, Nao / Hattori, Naoko / Nakamura, Hideaki / Sato, Akemi / Kawaguchi, Atsushi / Sueoka-Aragane, Naoko / Kojima, Kensuke / Okada, Seiji / Ushijima, Toshikazu / Kimura, Shinya / Sueoka, Eisaburo

    Blood

    2020  Volume 136, Issue 7, Page(s) 871–884

    Abstract: Adult T-cell leukemia-lymphoma (ATL) is an aggressive hematological malignancy of CD4+ T cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Most HTLV-1-infected individuals are asymptomatic, and only 3% to 5% of carriers develop ATL. Here, ... ...

    Abstract Adult T-cell leukemia-lymphoma (ATL) is an aggressive hematological malignancy of CD4+ T cells transformed by human T-cell lymphotropic virus-1 (HTLV-1). Most HTLV-1-infected individuals are asymptomatic, and only 3% to 5% of carriers develop ATL. Here, we describe the contribution of aberrant DNA methylation to ATL leukemogenesis. HTLV-1-infected T-cells and their uninfected counterparts were separately isolated based on CADM1 and CD7 expression status, and differentially methylated positions (DMPs) specific to HTLV-infected T cells were identified through genome-wide DNA methylation profiling. Accumulation of DNA methylation at hypermethylated DMPs correlated strongly with ATL development and progression. In addition, we identified 22 genes downregulated because of promoter hypermethylation in HTLV-1-infected T cells, including THEMIS, LAIR1, and RNF130, which negatively regulate T-cell receptor (TCR) signaling. Phosphorylation of ZAP-70, a transducer of TCR signaling, was dysregulated in HTLV-1-infected cell lines but was normalized by reexpression of THEMIS. Therefore, we hypothesized that DNA hypermethylation contributes to growth advantages in HTLV-1-infected cells during ATL leukemogenesis. To test this idea, we investigated the anti-ATL activities of OR-1200 and OR-2100 (OR21), novel decitabine (DAC) prodrugs with enhanced oral bioavailability. Both DAC and OR21 inhibited cell growth, accompanied by global DNA hypomethylation, in xenograft tumors established by implantation of HTLV-1-infected cells. OR21 was less hematotoxic than DAC, whereas tumor growth inhibition was almost identical between the 2 compounds, making it suitable for long-term treatment of ATL patient-derived xenograft mice. Our results demonstrate that regional DNA hypermethylation is functionally important for ATL leukemogenesis and an effective therapeutic target.
    MeSH term(s) Administration, Oral ; Adult ; Aged ; Animals ; Antineoplastic Agents/administration & dosage ; Cell Transformation, Viral/drug effects ; Cell Transformation, Viral/genetics ; Cells, Cultured ; DNA Methylation/drug effects ; DNA Methylation/genetics ; Demethylation/drug effects ; Drugs, Investigational/therapeutic use ; Female ; Gene Expression Regulation, Leukemic/drug effects ; HTLV-I Infections/complications ; HTLV-I Infections/drug therapy ; HTLV-I Infections/genetics ; Human T-lymphotropic virus 1/drug effects ; Human T-lymphotropic virus 1/physiology ; Humans ; Leukemia-Lymphoma, Adult T-Cell/drug therapy ; Leukemia-Lymphoma, Adult T-Cell/genetics ; Mice ; Mice, Inbred BALB C ; Mice, Knockout ; Molecular Targeted Therapy/methods ; Pyridines/administration & dosage ; Xenograft Model Antitumor Assays ; Young Adult
    Chemical Substances Antineoplastic Agents ; Drugs, Investigational ; OR-2100 ; Pyridines
    Language English
    Publishing date 2020-04-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2019003084
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top